U.S. Markets closed

OncoSec Medical Incorporated (ONCS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.60-0.10 (-1.75%)
At close: 4:00PM EST

OncoSec Medical Incorporated

24 North Main Street
Pennington, NJ 08534
United States
855 662 6732

Full Time Employees42

Key Executives

NameTitlePayExercisedYear Born
Mr. Daniel J. O'Connor J.D.Pres, CEO & Director726.65kN/A1965
Mr. Robert J. DelAversano CPAPrincipal Accounting Officer & ControllerN/AN/A1972
Dr. Kim JaffeSr. Director of OperationsN/AN/AN/A
Dr. Christopher G. Twitty Ph.D.Chief Scientific OfficerN/AN/AN/A
Mr. Keir LoiaconoVP of Legal & Corp. Devel., Chief Compliance Officer, Gen. Counsel & Corp. Sec.N/AN/AN/A
Mr. Tu DiepSr. VP & Head of OperationsN/AN/AN/A
Dr. Robert W. AshworthSr. VP of Regulatory, Quality & CMCN/AN/AN/A
Dr. Sandra Aung Ph.D.Sr. VP & Chief Clinical Devel. OfficerN/AN/AN/A
Dr. Mai Hope Le M.D.ConsultantN/AN/A1976
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


OncoSec Medical Incorporated, a biotechnology company, focuses on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 (IL-12) for reversing the immunosuppressive microenvironment in the treated tumor. It is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in Phase IIb clinical trials (KEYNOTE-695) and advanced or metastatic triple negative breast cancer (TNBC), which is in Phase II clinical trials (KEYNOTE-890); ImmunoPulse IL-12 and KEYTRUDA in patients with advanced or metastatic melanoma that has completed Phase II clinical trials; and ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma, which has completed the Phase II clinical trials. In addition, the company is developing monotherapy biomarker study in patients with advanced or metastatic TNBC that has completed the Phase II clinical trials; and new DNA-encoded therapeutic candidates and tumor indications to treat deep visceral lesions, such as liver, lung, bladder, pancreatic, and other visceral lesions. It has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890 studies; a research collaboration with Duke University's Center for Applied Therapeutics to evaluate enhanced IL-12 DNA-plasmid; a research collaboration with Roswell Park Comprehensive Cancer Center to evaluate the use of Roswell Park's intravital microscopy and enhanced IL-12 DNA-plasmid; and collaboration with Providence Cancer Institute. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was founded in 2008 and is headquartered in Pennington, New Jersey.

Corporate Governance

OncoSec Medical Incorporated’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.